|
Name |
1-Pyrrolidinamine
|
Molecular Formula | C4H10N2 | |
IUPAC Name* |
pyrrolidin-1-amine
|
|
SMILES |
C1CCN(C1)N
|
|
InChI |
InChI=1S/C4H10N2/c5-6-3-1-2-4-6/h1-5H2
|
|
InChIKey |
SBMSLRMNBSMKQC-UHFFFAOYSA-N
|
|
Synonyms |
1-Aminopyrrolidine; pyrrolidin-1-amine; 16596-41-1; 1-Pyrrolidinamine; N-Aminopyrrolidine; Pyrrolidine, 1-amino-; aminopyrrolidine; DF424U7HM6; NSC-80647; pyrrolidin-1-ylamine; pyrrolidylamine; NSC80647; NSC 80647; UNII-DF424U7HM6; DTXSID40168052; ALBB-032445; MFCD07368381; ZINC19167244; AKOS003582850; DB-005671; BB 0218179; FT-0601174; P2560; A26943; EN300-201007; F13227; 596A411; A810683; J-524150
|
|
CAS | 16596-41-1 | |
PubChem CID | 27946 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 86.14 | ALogp: | -0.6 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 29.3 | Aromatic Rings: | 1 |
Heavy Atoms: | 6 | QED Weighted: | 0.431 |
Caco-2 Permeability: | -4.498 | MDCK Permeability: | 0.00002310 |
Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0.026 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.004 |
Blood-Brain-Barrier Penetration (BBB): | 0.524 | Plasma Protein Binding (PPB): | 6.09% |
Volume Distribution (VD): | 1.368 | Fu: | 87.77% |
CYP1A2-inhibitor: | 0.094 | CYP1A2-substrate: | 0.258 |
CYP2C19-inhibitor: | 0.03 | CYP2C19-substrate: | 0.818 |
CYP2C9-inhibitor: | 0.003 | CYP2C9-substrate: | 0.087 |
CYP2D6-inhibitor: | 0.021 | CYP2D6-substrate: | 0.736 |
CYP3A4-inhibitor: | 0.005 | CYP3A4-substrate: | 0.261 |
Clearance (CL): | 8.092 | Half-life (T1/2): | 0.663 |
hERG Blockers: | 0.028 | Human Hepatotoxicity (H-HT): | 0.834 |
Drug-inuced Liver Injury (DILI): | 0.047 | AMES Toxicity: | 0.177 |
Rat Oral Acute Toxicity: | 0.863 | Maximum Recommended Daily Dose: | 0.048 |
Skin Sensitization: | 0.812 | Carcinogencity: | 0.966 |
Eye Corrosion: | 0.99 | Eye Irritation: | 0.979 |
Respiratory Toxicity: | 0.975 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001349 | 0.289 | D0N3PE | 0.267 | ||||
ENC001303 | 0.239 | D0Y2CJ | 0.255 | ||||
ENC000244 | 0.233 | D0L0MK | 0.193 | ||||
ENC000731 | 0.231 | D0X0WU | 0.193 | ||||
ENC000885 | 0.231 | D0Q4YK | 0.189 | ||||
ENC000817 | 0.222 | D00YZA | 0.179 | ||||
ENC000895 | 0.219 | D09FJB | 0.169 | ||||
ENC000183 | 0.214 | D01UUD | 0.169 | ||||
ENC001201 | 0.214 | D0E1XL | 0.167 | ||||
ENC001453 | 0.208 | D04QLR | 0.164 |